Last reviewed · How we verify
Tetracaine HCl and oxymetazoline HCl nasal spray
Tetracaine HCl and oxymetazoline HCl nasal spray is a Small molecule drug developed by University of North Carolina, Chapel Hill. It is currently FDA-approved.
Tetracaine HCl and oxymetazoline HCl nasal spray, developed by the University of North Carolina, Chapel Hill, is a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its unique combination of anesthetic and decongestant properties, which differentiates it in the nasal spray market. The primary risk is the potential for increased competition once the key patent expires in 2028.
At a glance
| Generic name | Tetracaine HCl and oxymetazoline HCl nasal spray |
|---|---|
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Tetracaine/Oxymetazoline Nasal Spray for Endodontic Treatment (PHASE4)
- Dose-Escalation Safety and Pharmacokinetic Study of K305 (PHASE2)
- Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients (PHASE3)
- Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection) (PHASE2)
- Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia (PHASE2)
- Safety and Pharmacokinetics of Kovacaine Nasal Spray in Pediatric Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tetracaine HCl and oxymetazoline HCl nasal spray CI brief — competitive landscape report
- Tetracaine HCl and oxymetazoline HCl nasal spray updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI